By 2023, marketers will no longer have access to third-party cookies on Google Chrome. The move aligns with the policy of Apple Safari and Mozilla Firefox, which have already blocked third-party cookies and left Chrome representing 92 percent of the remaining cookies on the internet. Many pharmaceutical brands have not invested solely in a cookie-based approach over the years, so those marketers were able to pursue additional marketing tactics on endemic and Point of Care channels to engage physicians during campaigns.

Intellia Therapeutics and Regeneron Pharmaceuticals shook the biotech and CRISPR world on June 26, announcing positive early data from the first-ever patients to have their DNA edited with an in vivo CRISPR/Cas9 therapy delivered systemically.

Lilly

Eli Lilly’s investigational diabetes drug tirzepatide is showing significant promise in targeting A1C levels and weight loss in patients with type 2 diabetes, including those who had never been previously treated for the disease. In other positive clinical results presented at the American Diabetes Association’s 81st Scientific Sessions meeting, Novo Nordisk data demonstrated an investigational 2mg dose of injectable Ozempic (semaglutide) generated statistically significant and superior reductions in A1C compared to a 1mg dose of Ozempic.

A mixed schedule of vaccines where a shot of Pfizer’s Covid-19 vaccine is given four weeks after an AstraZeneca shot will produce better immune responses than giving another dose of AstraZeneca, an Oxford study said on June 28.

AstraZeneca Plc’s diabetes drug significantly reduced blood sugar levels in adolescents aged 10–17 with type 2 diabetes in a late-stage study, the UK-based drugmaker said.

Fulcrum Therapeutics achieved what the company is calling a clinical first. Data from a Phase IIb study showed that using losmapimod to treat facioscapulohumeral muscular dystrophy (FSHD) slowed the progression of the disease and demonstrated improved function in patients. 

Eli Lilly will apply for U.S. health regulator’s accelerated approval during 2021 for the company’s experimental Alzheimer’s drug, weeks after Biogen Inc.’s controversial drug for the disease was approved.

Roche

Roche presented results from several Phase II and III trials at the 7th Congress of the European Academy of Neurology (EAN) Annual Meeting held virtually June 19-22.

Younger adults are seeking out Covid-19 vaccines at a slower rate than older adults, and if that pace of vaccination continues through August, vaccine coverage among younger adults will not reach levels achieved with older adults, U.S. Centers for Disease Control and Prevention (CDC) reported on June 21.

Gilead Sciences Inc. said an analysis showed the company’s antiviral remdesivir reduced mortality rates in hospitalized patients with Covid-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment.